Intervention

Immunotherapy allogeneic GM-CSF secreting cellular vaccine

ClinicalTrials.gov intervention label

Clinical trials5

Recruiting0

Common conditions1

Lead sponsors shown1

Clinical trials

5 shown

Docetaxel in Combination With GVAX ® Immunotherapy Versus Docetaxel and Prednisone in Prostate Cancer PatientsNCT00133224 · 2005-07-01

Dose Escalation and Efficacy Trial of GVAX® Prostate Cancer VaccineNCT00140348 · 2001-12-01

Prime-Boost Dose Scheduling Trial for Human GM-CSF Gene Transduced Irradiated Prostate Allogeneic Cancer Cell Vaccines (Allogeneic Prostate GVAX®)NCT00140387 · 1999-05-01

Prime-Boost Dose Scheduling Trial for Human GM-CSF Gene Transduced Irradiated Prostate Allogeneic Cancer Vaccine (Allogeneic Prostate GVAX®) in Patients With Hormone-Refractory Prostate CancerNCT00140400 · 1999-05-01

Vaccination Priming and Vaccine Boosting Trial of Allogeneic Human GM-CSF Gene Transduced Irradiated Prostate Cancer Cell Vaccines (GVAX® Vaccine for Prostate Cancer)NCT00140374 · 1998-12-01

Common conditions

Prostate Cancer5

Leading sponsors

Trial status mix

COMPLETED4

TERMINATED1

Phase mix

PHASE14

PHASE24

PHASE31

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.